The Safety and Effectiveness of Antifungal Medications in the Management of Mucormycosis during the COVID-19 Pandemic

Curr Drug Saf. 2024;19(1):3-7. doi: 10.2174/1574886318666230409145228.

Authors

Dhanya Jose¹, Krishna S Nair², Murali Alagesan², Joseph M Pappachan^{3

4}

Affiliations

¹ Department of Community Medicine, Goa Medical College, Goa, India.
² Department of General Medicine, P.S.G. Hospitals & Research Center, Coimbatore, Tamil Nadu, India.
³ Department of Endocrinology & Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston, UK.
⁴ Faculty of Science, Manchester Metropolitan University, All Saints Building, Manchester, M15 6BH, UK.

PMID: 37031384
DOI: 10.2174/1574886318666230409145228

No abstract available

MeSH terms

Antifungal Agents / adverse effects
COVID-19*
Humans
Mucormycosis* / drug therapy
Mucormycosis* / epidemiology
Pandemics

Substances

Antifungal Agents